Monthly Archives: May 2017

SNMMI Comments to FDA on Compounding

Posted on May 5, 2017 by

SNMMI submitted comments to the FDA on draft guidance “Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies.” The guidance explains that, under current law, radiopharmaceuticals compounded or repackaged by state-licensed nuclear pharmacies and federal facilities are subject to all … Continue reading →

Posted in PET Drugs | Leave a comment